Skip to main content
. 2022 Jan 18;17(1):e0262104. doi: 10.1371/journal.pone.0262104

Fig 3. Urinary TG2 and ε-(γ-glutamyl)-lysine excretion in CKD patients at different stages.

Fig 3

Average UTCR (A) and UXCR (D) in all CKD patients subdivided by the disease stages. Control group, n = 33; CKD stage 1, n = 11; CKD stage 2, n = 20; CKD stage 3A, n = 39; CKD stage 3B, n = 73; CKD stage 4, n = 132; CKD stage 5, n = 13. (B) and (E) show data from DKD patients, (C) and (F) show data from CGN patients. Statistical significance is shown by one-way ANOVA with Bonferroni post hoc test: *P < 0.05, **P < 0.01, ***P < 0.001 between CKD patients and HV. Data are mean ± SD. CGN = chronic glomerulonephritis; CKD = chronic kidney disease; DKD = diabetic kidney disease; HV = healthy volunteer; NS = not statistically significant; SD = standard deviation; TG2 = transglutaminase 2; UTCR = urinary TG2:creatinine ratio; UXCR = urinary ε-(γ-glutamyl)-lysine:creatinine ratio; XL = ε-(γ-glutamyl)-lysine crosslink.